The effect of butylscopolamine on [(18)F]FDG uptake in the gastrointestinal tract is negligible and regionally variable

BACKGROUND: Butylscopolamine (or hyoscine butylbromide, trade name Buscopan(®)) is occasionally administered as a premedication to reduce non-specific FDG uptake in the gastrointestinal tract based on its antiperistaltic effect. To date, there are no consistent recommendations for its use. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gühne, Falk, Ndum, Ferdinand, Seifert, Philipp, Winkens, Thomas, Drescher, Robert, Freesmeyer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281937/
https://www.ncbi.nlm.nih.gov/pubmed/37340145
http://dx.doi.org/10.1186/s13550-023-01012-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281937/
https://www.ncbi.nlm.nih.gov/pubmed/37340145
http://dx.doi.org/10.1186/s13550-023-01012-2

Ejemplares similares